Solid Biopterin Composition for Oxidation-Stable IV Use
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biopterin derivatives are sensitive to oxidation when stored in liquid form, making them unsuitable for long-term stability and easy use in therapeutic applications.
Innovation Solution
Development of solid pharmaceutical compositions comprising biopterin derivatives and phosphate salts, which are stable and easy to use, allowing for intravenous administration by mixing with a pharmaceutically acceptable carrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If biopterin derivatives are formulated in liquid form for therapeutic administration, then ease of operation is improved, but stability deteriorates due to oxidation sensitivity
Solution Approach 1:
The patent changes the physical state parameter from liquid to solid form for the biopterin derivative formulation. This parameter change resolves the contradiction by providing a stable solid composition that can be easily converted to liquid form only when needed for administration, thus maintaining stability during storage while ensuring ease of operation during use
Solution Approach 2:
The patent prepares the biopterin derivative in solid form in advance with stabilizing agents incorporated. This preliminary action prevents oxidation before it can occur, allowing the composition to be stored stably and then converted to liquid form only when ready for administration, resolving the contradiction between stability and ease of use
2Ease of operation
If biopterin derivatives are stored in solution form, then ease of operation is improved, but duration of action deteriorates due to oxidation over time
Solution Approach 1:
The patent changes the physical state from liquid solution to solid form, fundamentally altering the storage characteristics. This enables long-term storage without oxidation while maintaining ease of use through simple reconstitution or dissolution before administration
Solution Approach 2:
The solid composition incorporates stabilizing agents that create a protective environment around the biopterin derivative, preventing oxidation. This inert environment maintains the compound's stability during long-term storage while allowing easy conversion to active form when needed
3Stability of the object's composition
If solid pharmaceutical compositions are developed for biopterin derivatives, then stability is improved, but device complexity increases due to formulation requirements
Solution Approach 1:
The patent creates a composite material by combining the biopterin derivative with stabilizing agents in a solid matrix. This composite formulation enhances stability while maintaining relative simplicity through the use of compatible pharmaceutical excipients that do not significantly increase complexity
Solution Approach 2:
The solid composition is designed as a stable, long-term storage form that is converted to liquid form only when needed for administration. This approach uses a simple, stable solid formulation that can be easily converted to the required liquid form, avoiding the need for complex liquid formulations with multiple stabilizing systems
Data Source
AI summary
Disclosed is a method of method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solution of a solid pharmaceutical composition containing a compound of formula (I) and/or formula (II), wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, witha compound having formula (I) being:and a compound having the formula (II) being: